CUSIP No. M8737E108
|
Page 2 of 17 Pages
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
SUN PHARMACEUTICAL INDUSTRIES LTD.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
PF
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
The Republic of India
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
29,497,813*
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
29,497,813
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
29,497,813
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
66.3%**
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
CO
|
CUSIP No. M8737E108
|
Page 3 of 17 Pages
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
SUN PHARMA GLOBAL INC.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
PF
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
The British Virgin Islands
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
27,164,011*
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
27,164,011
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
27,164,011
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
61.0%**
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
CO
|
CUSIP No. M8737E108
|
Page 4 of 17 Pages
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
ALKALOIDA CHEMICAL COMPANY EXCLUSIVE GROUP LTD
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
PF
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
The Republic of Hungary
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
27,105,511*
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
27,105,511
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
27,105,511
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
60.9%**
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
CO
|
CUSIP No. M8737E108
|
Page 5 of 17 Pages
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
SUN PHARMACEUTICAL INDUSTRIES, INC.
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
PF
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Michigan
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
2,333,802*
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
2,333,802
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,333,802
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.2%**
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
CO
|
CUSIP No. M8737E108
|
Page 6 of 17 Pages
|
1
|
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
THE TARO DEVELOPMENT CORPORATION
|
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) x
|
|
||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (See Instructions)
PF
|
|||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
|
o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
New York
|
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
0
|
||
8
|
SHARED VOTING POWER
2,333,802*
|
|||
9
|
SOLE DISPOSITIVE POWER
0
|
|||
10
|
SHARED DISPOSITIVE POWER
2,333,802
|
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,333,802
|
|||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
|
o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.2%**
|
|||
14
|
TYPE OF REPORTING PERSON (See Instructions)
CO
|
ITEM 2.
|
IDENTITY AND BACKGROUND
|
Name
|
Address
|
Present
Principal Occupation
|
Citizenship
|
|||
Dilip S. Shanghvi
|
c/o Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Chairman & Managing Director
|
Indian
|
|||
Sudhir V. Valia
|
c/o Sun Pharmaceutical Industries Limited, Acme Plaza, Andheri Kurla Road, Andheri (East), Mumbai – 400 059, India
|
Director
|
Indian
|
|||
Sailesh T. Desai
|
c/o Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Director
|
Indian
|
|||
S. Mohanchand Dadha
|
c/o Sun Pharmaceutical Industries Limited, 10, Jeypore Nagar, Chennai - 600 086, India
|
Director
|
Indian
|
|||
Hasmukh S. Shah
|
c/o Sun Pharmaceutical Industries Limited, 402, 4th Floor, R. K. Centre, Fatehgunj Main Road, Baroda – 390 002, India
|
Director
|
Indian
|
|||
Keki Minu Mistry
|
c/o HDFC Limited, Ramon House, 5th Floor, H. T. Parekh Marg, 169, Backbay Reclamation, Churchgate, Mumbai – 400 020, India
|
Director
|
Indian
|
|||
Ashwin S. Dani
|
c/o Asian Paints (India) Limited, 6-A, Shanti Nagar, Santacruz (East), Mumbai – 400 055, India
|
Director
|
Indian
|
|||
Subramanian Kalyansundaram
|
c/o Sun Pharmaceutical Industries Ltd. Acme Plaza, Andheri Kurla Road, Andheri (East) Mumbai – 400 059, India
|
Chief Executive Officer and Director
|
New Zealand
|
Name
|
Address
|
Present
Principal Occupation
|
Citizenship
|
|||
Rakesh Mehta
|
Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093 India
|
Sr. Vice President, (International Marketing)
|
Indian
|
|||
Abhay Gandhi
|
Sun Pharmaceutical Industries Limited, Acme Plaza, Andheri Kurla Road, Andheri (E) Mumbai – 400 059, Maharashtra, India
|
Exec. Vice President, (International Marketing)
|
Indian
|
|||
T. K. Roy
|
Sun Pharmaceutical Industries Limited, Acme Plaza, Andheri Kurla Road, Andheri (E) Mumbai – 400 059, Maharashtra, India
|
Sr. Vice President (Marketing & Sales)
|
Indian
|
|||
Sharda Crishna
|
Sun Pharmaceutical Industries Limited, Acme Plaza, Andheri Kurla Road, Andheri (E) Mumbai – 400 059, Maharashtra, India
|
Sr. Vice President (Marketing & Sales)
|
Indian
|
Name
|
Address
|
Present
Principal Occupation
|
Citizenship
|
|||
Kirti Ganorkar
|
Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Sr. Vice President (Business Development)
|
Indian
|
|||
Vipul Doshi
|
Sun Pharmaceutical Industries Limited, SPARC, Tandalja, Vadodara-390 020, Gujarat, India
|
Exec. Vice President (Quality)
|
Indian
|
|||
Dr. Ratnesh Shrivastava
|
Sun Pharmaceutical Industries, Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Vice President (Intellectual Property Cell)
|
Indian
|
|||
Sampad Bhattacharya
|
Sun Pharmaceutical Industries Limited, Halol Baroda Highway, Halol 389 350, India
|
Vice President Operations
|
Indian
|
|||
Uday Baldota
|
Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Sr. Vice President (Investor Relations)
|
Indian
|
|||
A. H. Khan
|
Sun Pharmaceutical Industries Limited, Acme Plaza, Andheri Kurla Road, Andheri (E) Mumbai – 400 059 Maharashtra, India
|
Vice President (Human Resources Development)
|
Indian
|
|||
Dinesh R. Desai
|
Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Vice President (Accounts)
|
Indian
|
|||
Sunil Ajmera
|
Sun Pharmaceutical Industries Limited, 401-404, The Eagle’s Flight, Dr. Suren Road, Off Andheri-Kurla Road, Chakala, Andheri (East) Mumbai, 400 093, India
|
Sr. General Manager (Operations), Compliance Officer & Company Secretary
|
Indian
|
|||
Ashok I. Bhuta
|
Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Deputy General Manager (Legal & Secretarial) & Compliance Officer
|
Indian
|
|||
Pabitra Kumar Bhattacharya
|
Sun Pharmaceutical Industries Limited, 401-404, The Eagle’s Flight, Dr. Suren Road, Off Andheri-Kurla Road, Chakala, Andheri (East) Mumbai, 400 093, India
|
Vice President (Process Engg. & Operations)
|
Indian
|
|||
Sunil P. Mehta
|
Sun Pharmaceutical Industries Limited, 17/B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East), Mumbai 400 093, India
|
Vice President
|
Indian
|
|||
B.F. Shirude
|
Sun Pharmaceutical Industries Limited, A-8, MIDC Industrial Area, Ahmednagar 414 111, India
|
Vice President Operations (API)
|
Indian
|
|||
R. S. Vasan
|
Sun Pharmaceutical Industries Limited, Acme Plaza, Andheri Kurla Road, Andheri (E) Mumbai 400 059 Mahrashtra, India
|
Sr. Vice President (Marketing & Sales)
|
Indian
|
Names
|
Address
|
Present Principal Occupation
|
Citizenship
|
|||
Harin Mehta
|
Flat no. 3,1, Elmunkas street, Tiszavasvari, Hungary - 4440
|
Director
|
Indian
|
|||
Sunil Gandhi
|
SuGandhManagement, Consultancy, Woodstock Asia Pacific DMCC, Office No. 406, The Business Centre, Opp Burjuman Centre, Mashreq Bank Bldg. Bank Street, P.O. Box 12850, Dubai-UAE
|
Director & Secretary of Sun Global and Financial Consultant
|
Indian
|
|||
Surendra Joshi
|
PO Box 696, Muttrah, Post Code No. 114, Sultanate of Oman
|
Director of Sun Global and Tax Consultant
|
Indian
|
Name
|
Address
|
Present
Principal Occupation
|
Citizenship
|
|||
Harin Mehta
|
Flat no. 3,1, Elmunkas street, Tiszavasvari, Hungary – 4440.
|
Managing Director, Sun Pharma Global Inc.
|
Indian
|
|||
Jayesh Shah
|
Caraco Pharmaceutical Laboratories Limited,
1150 Elijah McCoy Drive, Detroit, MI 48202, USA.
|
Director-Commercial, Caraco Pharmaceutical Laboratories Limited.
|
United States
|
|||
Katalin Szilágyi
|
4440 Tiszavasvári, Kelp Ilona u. 3., Hungary.
|
Director,
Quality Assurance & Quality Control, Alkaloida Chemical Company Exclusive Group Ltd.
|
Hungarian
|
|||
Sudhir V. Valia
|
Acme Plaza, Andheri Kurla Road, Andheri (East), Mumbai 400 059, India.
|
Professional Company Directorships
|
Indian
|
Name
|
Address1
|
Present
Principal Occupation
|
Citizenship
|
|||
Gyula Sotkó
|
Alkaloida Chemical Company Exclusive Group Ltd.
|
Purchasing & Logistics Manager
|
Hungarian
|
|||
Katalin Szilágyi
|
Alkaloida Chemical Company Exclusive Group Ltd.
|
Director, Quality Assurance & Quality Control
|
Hungarian
|
|||
Dr. József Simon
|
Alkaloida Chemical Company Exclusive Group Ltd.
|
Chief Legal Advisor
|
Hungarian
|
|||
Zoltán Nagy
|
Alkaloida Chemical Company Exclusive Group Ltd.
|
Human Resources Manager
|
Hungarian
|
|||
Tibor Horváth
|
4026 Debrecen, Hatvan u. 1/C.III/3. The Republic of Hungary.
|
Poppy System Manager
|
Hungarian
|
|||
Zoltán László
|
Alkaloida Chemical Company Exclusive Group Ltd.
|
Technical Supply Manager
|
Hungarian
|
|||
Ferenc Vicsai
|
Alkaloida Chemical Company Exclusive Group Ltd.
|
Controlling Manager
|
Hungarian
|
|||
Tamás Udvari
|
1092 Budapest, Ráday u. 16. I/22. The Republic of Hungary.
|
Finance Manager
|
Hungarian
|
Name
|
Address
|
Present
Principal Occupation
|
Citizenship
|
|||
GP. Singh
|
30600 Telegraph Road, Bingham Farms, MI 48025
|
Director and President of Sun Michigan
|
United States
|
|||
Jayesh M Shah
|
30600 Telegraph Road, Bingham Farms, MI 48025
|
Director
|
United States
|
|||
Sudhir V Valia
|
30600 Telegraph Road, Bingham Farms, MI 48025
|
Director
|
Indian
|
Name
|
Address
|
Present
Principal Occupation
|
Citizenship
|
|||
John Dauer
|
30600 Telegraph Road, Bingham Farms, MI 48025
|
Vice President
|
United States
|
|||
James Hattersley
|
30600 Telegraph Road, Bingham Farms, MI 48025
|
Vice President
|
United States
|
|||
Abramowitz Wattanaporn
|
30600 Telegraph Road, Bingham Farms, MI 48025
|
Vice President
|
United States
|
Name
|
Address
|
Present
Principal Occupation
|
Citizenship
|
|||
Rajesh Shah
|
270 Prospect Plains Road, Cranbury, NJ 08512
|
Director | Indian | |||
Jayesh M Shah
|
Caraco Pharmaceutical Laboratories Limited,
1150 Elijah McCoy Drive, Detroit, MI 48202
|
Director
|
United States
|
|||
Sudhir V Valia
|
30600 Telegraph Road, Bingham Farms, MI 48025
|
Director
|
Indian |
ITEM 4.
|
Purpose of Transaction
|
|
·
|
3,770,833 Ordinary Shares acquired by Alkaloida on May 21, 2007 pursuant to the Purchase Agreement;
|
|
·
|
3,016,667 Ordinary Shares acquired by Alkaloida on May 30, 2007 pursuant to the Purchase Agreement;
|
|
·
|
58,000 Ordinary Shares acquired by Sun Pharma, a direct wholly-owned subsidiary of Sun, on July 11, 2007 in open market transactions;
|
|
·
|
500 Ordinary Shares acquired by Sun Pharma on July 23, 2007 in open market transactions;
|
|
·
|
3,000,000 Ordinary Shares acquired by Alkaloida on August 2, 2007, pursuant to the Original Warrant;
|
|
·
|
3,712,557 Ordinary Shares acquired by Alkaloida on February 19, 2008 from Brandes;
|
|
·
|
797,870 Ordinary Shares acquired by Alkaloida on June 23, 2008 from Harel;
|
|
·
|
3,787,500 Ordinary Shares which Alkaloida acquired pursuant to Warrant No. 2, including (i) 3,712,500 Ordinary Shares issued to Alkaloida on September 24, 2010 and (ii) 75,000 Ordinary Shares issued to Alkaloida on September 27, 2010;
|
|
·
|
29,382 Ordinary Shares which Alkaloida directly acquired on September 14, 2010, upon the closing of the initial offering period of the tender offer to purchase all of the outstanding Ordinary Shares, pursuant to the Tender Offer Statement on Schedule TO, filed on June 30, 2008, as amended;
|
|
·
|
4,739,739 Ordinary Shares indirectly acquired by Sun pursuant to the Letter Agreement as follows: (i) Alkaloida directly acquired 2,405,925 Ordinary Shares from the Grantors, consummating the Option Agreement, dated May 18, 2007, among the Grantors and Sun (and subsequently assigned to Alkaloida), (ii) Alkaloida directly acquired an additional 12 Ordinary Shares from the Grantors, and (iii) upon the merger of a subsidiary of Sun Michigan with and into TDC on October 1, 2010, Sun Michigan indirectly acquired 2,333,802 Ordinary Shares, consummating an option granted by TDC to Alkaloida (and subsequently assigned to Sun Michigan) under the Option Agreement;
|
|
·
|
5,159,765 Ordinary Shares acquired by Alkaloida on November 1, 2010 from Franklin Advisors, Inc. and Templeton Asset Management Ltd.;
|
|
·
|
712,500 Ordinary Shares acquired by Alkaloida on January 18, 2011 under the Purchase Agreement;
|
|
·
|
712,500 Ordinary Shares acquired by Alkaloida on January 18, 2011 pursuant to Warrant No. 2; and
|
|
·
|
2,600 Founders’ Shares acquired by Alkaloida, in connection with the consummation of the transactions contemplated by the Option Agreement.
|
ITEM 5.
|
Interest in Securities of the Issuer
|
ITEM 7.
|
Materials to be Filed as Exhibits
|
Exhibit
|
Description
|
99.42
|
Agreement of Joint Filing, dated as of July 2, 2007, incorporated by reference to the Original Schedule 13D.
|
99.43
|
Joinder Agreement, dated as of September 24, 2010, incorporated by reference to Amendment No. 19.
|
99.44
|
Second Joinder Agreement, dated as of October 18, 2011 (filed herewith).
|
99.45
|
Letter to the Board of Directors of Taro Pharmaceutical Industries Ltd., dated October 18, 2011 (filed herewith).
|
SUN PHARMACEUTICAL INDUSTRIES LIMITED
|
|
By: /s/ Sudhir V. Valia
|
|
Name: Sudhir V. Valia
|
|
Title: Director
|
|
SUN PHARMA GLOBAL, INC
|
|
By: /s/ Harin Mehta
|
|
Name: Harin Mehta
|
|
Title: Director
|
|
ALKALOIDA CHEMICAL COMPANY EXCLUSIVE GROUP LIMITED
|
|
By: /s/ Harin Mehta
|
|
Name: Harin Mehta
|
|
Title: Director
|
|
SUN PHARMACEUTICAL INDUSTRIES, INC.
|
|
By: /s/ Jayesh M. Shah
|
|
Name: Jayesh M. Shah
|
|
Title: Authorized Signatory
|
|
THE TARO DEVELOPMENT CORPORATION
|
|
By: /s/ Rajesh Shah
|
|
Name: Rajesh Shah
|
|
Title: Authorized Signatory
|
|
Exhibit
|
Description
|
99.42
|
Agreement of Joint Filing, dated as of July 2, 2007, incorporated by reference to the Original Schedule 13D.
|
99.43
|
Joinder Agreement, dated as of September 24, 2010, incorporated by reference to Amendment No. 19.
|
99.44
|
Second Joinder Agreement, dated as of October 18, 2011 (filed herewith).
|
99.45
|
Letter to the Board of Directors of Taro Pharmaceutical Industries Ltd., dated October 18, 2011 (filed herewith).
|
THE TARO DEVELOPMENT CORPORATION
|
|
By: /s/ Rajesh Shah
|
|
Name: Rajesh Shah
|
|
Title: Authorized Signatory
|
|
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685
|
![]() |
Sincerely,
|
||
SUN PHARMACEUTICAL INDUSTRIES LIMITED
|
||
By:
|
/s/ Dilip Shanghvi
|
|
Name:
|
Dilip Shanghvi
|
|
Title:
|
Chairman & Managing Director | |